Journal of Clinical Oncology

Vol. 43, Issue 25 Issue 25 2025

Articles

Articles in this Issue

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203

Ivan Marquez-Rodas, Caroline Dutriaux, Philippe Saiag et al. Sep 01, 2025 pp. 2840-2840 10.1200/jco-25-01680

Random Assignment, But Without Comparison: A Missed Opportunity

Alexander D. Sherry, Ethan B. Ludmir, Pavlos Msaouel Sep 01, 2025 pp. 2836-2837 10.1200/jco-25-00998

Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia

Inna M. Chen, Julia S. Johansen, Susann Theile et al. Sep 01, 2025 pp. 2840-2840 10.1200/jco-25-01631

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Susana N. Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian et al. Sep 01, 2025 pp. 2782-2792 10.1200/jco-25-00112

PURPOSE This study evaluated the efficacy and safety of avutometinib (rapidly accelerated fibrosarcoma/mitogen-activated extracellular signal-regulated kinase [MEK] clamp) alone or...

Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching

Yutaka Shimazu Sep 01, 2025 pp. 2834-2834 10.1200/jco-25-00394

Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma

Georg C. Lodde, Jessica C. Hassel, Imke von Wasielewski et al. Sep 01, 2025 pp. 2793-2805 10.1200/jco-24-02776

PURPOSE Adjuvant treatment with immune checkpoint inhibition (PD-1) and targeted therapy (TT) with BRAF + MEK inhibitors significantly improved recurrence-free survival (RFS) of patients w...

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

Conor E. Steuer, Hidetoshi Hayashi, Wu-Chou Su et al. Sep 01, 2025 pp. 2816-2826 10.1200/jco-24-02744

PURPOSE Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HE...

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, Thomas G. Martin, Yi Lin et al. Sep 01, 2025 pp. 2766-2771 10.1200/jco-25-00760

CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free...

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Monzr M. Al Malki, Stephanie Bo-Subait, Brent Logan et al. Sep 01, 2025 pp. 2772-2781 10.1200/jco-25-00856

PURPOSE Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for advanced hematologic malignancies. HSCT using human leukocyte antigen (HLA)-mismatched donors...

BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203

Ivan Marquez-Rodas, Caroline Dutriaux, Philippe Saiag et al. Sep 01, 2025 pp. 2806-2815 10.1200/jco-24-02595

PURPOSE Patients with anti–PD-1–resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanople...